Showing 1561-1570 of 7030 results for "".
Scientifically Speaking: Nanopulse Stimulation with Darrin Uecker
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-nanopulse-stimulation-with-darrin-uecker/20111/The CellFX system from Pulse Biosciences is a true platform technology, says President/CEO Darrin Uecker. He talks to host Joel L. Cohen, MD about the technology, its application, and potential future uses.DermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More
https://practicaldermatology.com/topics/practice-management/dermwiretv-inclusion-in-derm-amgen-incyte-janssen-dermavant-updates-klisyri-launch-more/19901/For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using theirVaser Shape
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vaser-shape/19451/A description on the benefits of using VaserShape for reducing the appearance of cellulite along with a demonstration of the non-invasive ultrasound and massage therapy treatment.Mechanisms of Action for IL-17 Inhibition in Treating Psoriasis and Hidradenitis Suppurativa
https://reachmd.com/programs/practical-dermatology-il-17-journal-club/mechanisms-of-action-for-il-17-inhibition-in-treating-psoriasis-and-hidradenitis-suppurativa/48808/Practical Dermatology Editorial Board member Jason E. Hawkes, MD, MS, FAAD, joins Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss articles from the Journal of Clinical Medicine and Clinics in Dermatology on how IL-17 inhibition is effective in treating psoriasis and hidradenitis suppurativa,Trends in the Medical Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/trends-in-the-medical-aesthetic-market/24560/Ethan Min, CEO of Benev, discusses trends in the medical aesthetic market, including the potential impact that Glucagon-like peptide-1 (GLP-1) for weight loss will have on the aesthetics industry.What Should Dermatology PAs Look For in a Contract
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-look-contract/24164/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, shares insights into what dermatology PAs should think about for their employment contracts (particularly when starting out at their first practice). Some of the topicDermWireTV: Sun Hero Launch; Eczema Awareness Month; ASDSA Hails Hyaluron Pen Warning
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-sun-hero-launch-eczema-awareness-month-asdsa-hails-hyaluron-pen-warning/20006/An estimated 80% of skin damage occurs before age 18. L'Oreal brands CeraVe and LaRoche-Posay have teamed with Dr. Amy Brodsky to launch the Sun Hero campaign to educate young people about UV safety. Throughout Eczema Awareness month, the National Eczema Association is spotlighting aspects of the diDermWireTV: Doximity Physician Compensation Report, EADV Updates, PsO in the Know
https://practicaldermatology.com/topics/psoriasis/dermwiretv-doximity-physician-compensation-report-eadv-updates-pso-in-the-know/19870/Doximity’s fourth annual Physician Compensation Report shows a widening of the gender pay gap. From biologics and investigational molecules for psoriasis to socks to prevent foot odors, the European Academy of Dermatology and Venereology annual meeting highlights emerging therapies for dermatology pDermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaCrisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.